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Abstract
Background: Hypertension, hyperlipidemia, and diabetes are sig-
nificant, but often preventable, contributors to cardiovascular disease
(CVD) risk. Medication and behavioral nonadherence are significant
barriers to successful hypertension, hyperlidemia, and diabetes
management. Our objective was to describe the theoretical framework
underlying a tailored behavioral and educational pharmacist-
administered intervention for achieving CVD risk reduction. Mate-
rials and Methods: Adults with poorly controlled hypertension and/
or hyperlipidemia were enrolled from three outpatient primary care
clinics associated with the Durham Veterans Affairs Medical Center
(Durham, NC). Participants were randomly assigned to receive a
pharmacist-administered, tailored, 1-year telephone-based inter-
vention or usual care. The goal of the study was to reduce the risk for
CVD through a theory-driven intervention to increase medication
adherence and improve health behaviors. Results: Enrollment began
in November 2011 and is ongoing. The target sample size is 500
patients. Conclusions: The Cardiovascular Intervention Improve-
ment Telemedicine Study (CITIES) intervention has been designed
with a strong theoretical underpinning. The theoretical foundation
and intervention are designed to encourage patients with multiple
comorbidities and poorly controlled CVD risk factors to engage in
home-based monitoring and tailored telephone-based interventions.
Evidence suggests that clinical pharmacist-administered telephone-
based interventions may be efficiently integrated into primary care
for patients with poorly controlled CVD risk factors.
Key words: cardiology/cardiovascular disease, pharmacy, tele-
medicine
Introduction
C
ardiovascular disease (CVD) is the leading cause of death
for Americans.1 Hypertension, hyperlipidemia, and diabe-
tes are significant, often preventable contributors to CVD
risk. These risk factors are multiplicative; patients can de-
crease their probability of experiencing CVD by modifying dietary
habits, increasing physical activity, and making other lifestyle
changes. In addition, many patients with poorly controlled CVD risk
factors require pharmacological treatment to manage their condition.
In order for pharmacological regimens to be effective, medications
must be taken consistently as prescribed. An estimated 20–50% of
patients are nonadherent with their CVD medications.2 Medication
and behavioral nonadherence are significant barriers to successful
chronic disease management.3
There have been many efforts to reduce medication and behavioral
nonadherence to promote CVD health. The new paradigm in Veterans
Affairs (VA) Medical Centers for engaging patients in primary care is
the patient-aligned care team (PACT) or patient-centered medical
home.4,5 The core principles of PACT emphasize personal relation-
ships, team delivery of patient-centered care, coordination across
specialties, quality and safety improvements, open access, and value-
driven care.4,5
Previous studies demonstrate the merits of using telephone-based
interventions. Telephone-based care is often more convenient and
accessible for patients than in-person care.6–8 It may also reduce
patients’ travel cost, prevent clinic no-show appointments, and
supplement the need for clinic visits. Therefore, telephone-based
care may be critical in supporting the PACT vision of coordination
across different settings of care while improving access to care.
The professional role of the person making the telephone calls is
equally important. Pharmacists and nurses have successfully
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administered many previous hypertension interventions.7–11 Com-
pared with nurses, pharmacists provide the added benefit of medi-
cation management. The effectiveness of telephone-based
interventions is further increased by incorporating tailored infor-
mation and feedback.12–14 The purpose of this article is to describe
the underlying theoretical framework of the Cardiovascular Inter-
vention Improvement Telemedicine Study (CITIES) intervention.
Materials and Methods
THEORETICAL FRAMEWORK
A synthesis of the health belief model (HBM), the health decision
model (HDM), and the transtheoretical model (TTM) informed the
structure for this tailored intervention. The HBM is one of the earliest
social cognition models. The concept underlying HBM is that an
individual’s perceived personal threat and barriers to change, cou-
pled with his or her belief in the benefits and effectiveness of the
behavior change, will predict one’s likelihood of adopting a desired
behavior.15 The HDM builds on the HBM and incorporates decision
analysis, behavioral decision theory, and health beliefs to yield a
unified model of health decisions and resultant behavior. HDM fo-
cuses on health decisions and combines the influences of health
beliefs and modifying factors.16,17 HDM explains some of the un-
derlying behaviors affecting poor CVD control such as decisions to
cease smoking and/or adhere to a diet and exercise regimen. Despite
its theoretical value, HDM is not designed to comprehensively in-
clude the myriad of patient and clinical factors impacting blood
pressure (BP) control.18 The CITIES theoretical framework incorpo-
rates elements of both models, expanding to include patient char-
acteristics like medication-related side effects.
In tandem, the HBM and HDM are informative in ascertaining
factors that may explain medication adherence and subsequent BP
and cholesterol control. However, we need an additional framework
to explain factors that hinder or promote cardiovascular health be-
haviors. The TTM asserts that behavioral change occurs in a temporally
ordered series of stages.13 An individual is hypothesized to move be-
tween stages based on the ratio of pros and cons associated with the
behavior, self-efficacy, temptations to relapse, and coping mechanisms
used to change the problem behavior.13 To that end, the TTM describes
five stages categorizing an individual’s interest and motivation to
modify a problem behavior. The first stage, ‘‘precontemplation,’’ is the
stage when there is an unwillingness to change or there is a lack of
problem recognition. Second, ‘‘contemplation’’ involves reflecting on
the consequences of action or inaction of the problem behavior. At this
stage, participants conceptualize the advantages and disadvantages of,
for example, taking daily aspirin for heart attack prevention. Next, the
‘‘preparation’’ stage is when there is a commitment to change in the
near future. The ‘‘action’’ stage involves successfully modifying be-
havior for a period of 1 day to 6 months. Lastly, ‘‘maintenance’’ occurs
when an individual has engaged in the new behavior for 6 months or
more. Emphasis is placed on lifestyle modification to ensure that be-
havior change is sustained.14
Critical to the CITIES intervention is that it encompasses targeted,
tailored information and feedback, which has been demonstrated to
be effective for modifying multiple behaviors. The intervention is
targeted, for example, in that only participants who are actively
smoking are presented with the smoking cessation module. Tailored
interventions may have increased impact because they can be de-
signed to target issues of particular relevance to an individual.19 The
CITIES intervention content is tailored based on a participant’s level
of motivation to change, his or her knowledge and understanding of
treatment, and counseling on specific behavioral changes. Modules
are triggered based on a patient’s responses, such as average weekly
exercise. The pharmacist assesses the participant’s self-reported stage
of change, perceived barriers, and self-efficacy related to a health
behavior. During subsequent modules the patient’s most recent self-
reported stage of change is used to tailor content. For example,
during predesignated encounters participants are asked, on average,
how many hours they exercise weekly. Patients who exercise less
than recommended are asked how interested they are in changing
their current activity level. Responses reassess a patient’s readiness to
change (e.g., not ready to change at this time, thinking about
changing my activity level, preparing for changed activity level).
By integrating key components of theoretical models,13,17,20 the
CITIES intervention addresses how (1) to establish healthy goals and
gain self-efficacy, (2) to implement healthy behaviors, (3) to monitor
performance, and (4) to longitudinally maintain healthy behaviors
for CVD control. The intervention involves pharmacist-administered
telephone counseling tailored for individuals based on behavioral
and clinical needs.21 Although pharmacists may be more costly than
other professional interventionists, pharmacists are experts in drug
therapy. In addition, pharmacists are able to immediately respond to
changes in home-monitored values by adjusting medications. De-
spite the initial expense pharmacists may ultimately reduce cost by
improving patient adherence, thus decreasing unnecessary health-
care utilization.
INTERVENTION PROCEDURES
The pharmacist contacts the patients in the intervention arm by
telephone monthly for 1 year. At each call the pharmacist delivers
both tailored and standard information from study modules.22 This
monthly frequency was designed based on several factors, including
previous experience,2,20 clinical response, and response to goal set-
ting. One month allows sufficient elapsed time to note discernible
effects from medication changes, while still calling soon enough to
mitigate any potential adverse events. Similarly, the order of the
modules was clinically derived. For example, we address medication
adherence in the first pharmacist intervention module. Therefore,
specific barriers to medication adherence may be identified early as a
source of poor disease control. In subsequent modules medication
adjustments may be made to address barriers that a patient previ-
ously reported.
The pharmacist uses plain language and nonmedical terminolo-
gy23 and requests that patients confirm their understanding of edu-
cational information (e.g., teach back, set goals). To ensure that
participants in the intervention arm receive standardized informa-
tion, the pharmacist uses a computerized database that contains
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prescripted content and tailoring algorithms. The database also col-
lects information about the call contents and duration, when the
participant needs to be contacted again, and what occurred during
previous telephone encounters.
RECRUITMENT AND ENROLLMENT
Recruitment and enrollment procedures have been previously
described.22 In brief, potential CITIES participants are identified
through an electronic health record query to locate patients who were
enrolled in one of three primary care clinics affiliated with the
Durham VA Medical Center (Durham, NC). Eligible participants have
active outpatient diagnoses codes for hypertension and/or hyper-
lipidemia with poor control over the last 12 months and are 40 years
or older at the time of enrollment. Exclusion criteria include
the following: diagnosis of metastatic cancer, active diagnosis of
psychosis or dementia, on dialysis, or high creatinine levels (i.e.,
‡ 2.5 mg/dL), having had a stroke or myocardial infarction in the past
3 months, lack of access to a telephone at home, resident in a nursing
home or receiving home healthcare, severe hearing or vision im-
pairment, participation in another clinical trial or intervention, or a
plan to move their healthcare away from the VA. Patients currently
followed up for medication management by a PACT clinical phar-
macist specialist are also excluded.
Research assistants collect biometric information (e.g., height,
weight, BP) and administer the baseline questionnaire. Participants
are then randomized into one of two groups: the educational control
group or the pharmacist-intervention group. Randomization is
stratified based on three participant characteristics, including gender
(e.g., male versus female), smoking status (e.g., current smoker versus
nonsmoker), and diabetes status (e.g., diabetic versus not diabetic).
Participants in the control group (i.e., usual care) are given educa-
tional materials about CVD to review independently. Those in the
pharmacist-intervention group are given an intervention handbook
and trained on the use of home BP equipment and (if clinically ap-
propriate) the use of a glucometer. Participants are directed to the
laboratory for collection of a lipid panel and, if applicable, glyco-
sylated hemoglobin level.
Participants return for two additional in-person visits at 6 months
and 12 months after enrolling in the study. There is no physical
contact with the pharmacist during these encounters. A research
assistant collects biometric data again and re-administers the ques-
tionnaire. This procedure allows collection of repeated measures of
participants’ stage of change, enabling testing of the theoretical
components of the intervention.
SAMPLE SIZE CALCULATION AND SAMPLE
The sample size estimate is based on the hypothesis that patients in
the intervention group will have a greater reduction in their general
CVD risk profile compared with patients in the control group. This
hypothesis will be tested using the null hypothesis that there is no
between-group difference in risk at two follow-up time points (6 and
12 months). Sample size calculations were therefore performed to
evaluate the 2 degrees of freedom omnibus test contrasting the two
treatment groups at the two time points. Using preliminary data from
the V-STITCH study6 to estimate quantities needed for the sample size
calculation, a mean probability of CVD risk of 40% and a standard
deviation of 19.5% in both treatment groups at baseline are antici-
pated. The correlation between the different time points was assumed
to be 0.7. We generated sample size estimates for a differential in-
tervention group improvement of 6% by 12 months. For the example
patient, if his or her total cholesterol level improved to 185 mg/dL
and systolic BP improved to 148 mm Hg, the CVD risk profile would
be 35%, an improvement of 6%. Sample size and power were esti-
mated via methods and software discussed by Rochon.24 A two-sided
type-I error rate of 5% and a power of 80% were applied in all cal-
culations. The largest sample size for the omnibus test arises from the
fast initial decrease, so that a minimum of 197 participants per
treatment group is required, for a total study size of 394 participants.
Assuming that 15% of enrollees drop out before the Month 12
evaluation, we need to recruit 394/0.85 = 464 participants. A 15%
dropout rate is conservative; we typically have observed an ap-
proximately 10% dropout rate by 12 months in our prior trials.
Rounding this up to protect against deviations from our assumptions,
a total of 500 total participants (250 per arm) will be recruited and
started on the interventions. Based on prior recruitment experience,
this is a feasible goal.
The enrollment period began on November 1, 2011 and is ongoing.
The enrollment objective is 500 participants. A visual depiction of the
study timeline is presented in Table 1. The Durham VA Institutional
Review Board approved this study. All participants provided in-
formed consent.
INTERVENTION EDUCATIONAL MODULES
A critical component of the intervention is modifying and sus-
taining specific health behaviors to decrease CVD risk. Because CVD
risk factors are multiplicative, the intervention is designed to target
multiple behavioral factors simultaneously, creating a synergistic
result that is more effective than focusing on an individual problem
behavior. The intervention content is divided into modules, each
focusing on a specific element of CVD health and risk reduction,
which are combined and personalized to target behaviors relevant to
a particular patient (Table 2). These modules include medication
reconciliation, pill refill, disease knowledge/ risk perception, weight
management, diet, exercise, smoking cessation, stress reduction,
sleep apnea, insomnia, mental health, and hypoglycemia; these
factors are not only important to patients’ CVD outcome, but are also
topics for targeting and tailoring of intervention materials.22
MEDICATION ADHERENCE
During the initial medication adherence module, the pharmacist
and participant review all CVD-related medications, discuss the
purpose of participants’ medications, assess for safety, and go over
how the medications should be administered. Medication reconcili-
ation (i.e., knowing what the patient may have been prescribed based
on electronic records versus what the patient is actually taking)
serves as the cornerstone of this module. At subsequent contacts the
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pharmacist reviews recent medication changes via electronic records
with participants for patient understanding. Prior to each encoun-
ter, the pharmacist, before making medication adjustments exam-
ines both patient-reported and electronic health record data for
evidence of barriers to medication adherence. Participants who
repeatedly forget to take their medications are provided mnemonic
strategies. Memory adherence strategies provided to patients in-
clude cueing (e.g., pairing taking medication with an established
behavior such as brushing teeth), monitoring (e.g., using a calendar
to track medication taking), or utilizing a weekly pill reminder
container.
MEDICATION SIDE EFFECTS
The pharmacist queries the patient about specific side effects, such
as symptoms of hypotension and muscle pain, which may be com-
mon with antihypertensive and cholesterol medications, respec-
tively. The pharmacist provides education regarding signs and
symptoms to problematic side effects and encourages participants to
maintain adherence with their medication regimen based on a greater
benefit versus perceived risk. If a participant experiences a side effect,
the pharmacist explores how this might impact his or her medication
adherence and considers alternative solutions. In the event of a po-
tentially life-threatening side effect, the pharmacist immediately
contacts the provider.
During the baseline assessment participants are asked about bar-
riers to obtaining pill refills. Additionally, the pharmacist asked
whether participants are lacking pill refills or have difficulties ac-
quiring their prescriptions. For patients having difficulty, the phar-
macist educates participants about multiple methods for obtaining
refills through the VA.
KNOWLEDGE/RISK PERCEPTION
At baseline patients randomized to the intervention receive this
risk knowledge in two encounters. Encounter 1 includes (1) education
on CVD risk factors, both modifiable and nonmodifiable, (2) an ex-
planation of cholesterol and appropriate goals, and (3) the benefits
of anitplatelet therapy. During Encounter 2 participants receive ad-
ditional information on hypertension,
risks of uncontrolled hypertension, goals
of hypertension therapy, and (if clinically
indicated) education on diabetes risks
and goals of therapy.
HEALTH BEHAVIORS
The CITIES study informs patients
about several cardiovascular health be-
haviors like weight management, diet,
exercise, smoking habits, and stress re-
duction. Patients are provided the evi-
dence-based recommendations regarding
these behaviors and will be advised on how
to reduce lifestyle risk factors. There is
evidence that a healthcare provider’s rec-
ommendation is the most likely factor to instigate a change in health
behavior.25 Therefore, only those individuals identified as being over-
weight (body mass index > 25kg/m2), who report high levels of stress,
or who smoke at the time of contact receive information regarding
weight management, stress reduction, and smoking cessation, respec-
tively. The pharmacist uses motivational interviewing techniques, en-
gages S.M.A.R.T. strategies (i.e., specific, measureable, attainable,
realistic, timely) for individualized goal setting related to managing
cardiovascular-related behaviors, and sets specific action plans that
enable participants to progress toward their goals.
WEIGHT MANAGEMENT
Because readiness to change fluctuates over time, the pharma-
cist asks participants about their state of change regarding weight
loss during each in-person interview. With this information, the
pharmacist facilitates participants’ progression through the stages
of change by exploring potential barriers to health habits, using
motivational interviewing techniques, and setting exercise goals.
For participants with an elevated body mass index (e.g., ‡ 25 kg/
m2), the importance of maintaining a healthy weight is stressed
regardless of participants’ stage of change. The pharmacist also
ensures that participants set reasonable weight management
goals and reminds them that losing even 10 pounds carries health
benefits.
DIET
Dietary recommendations focus on improved cholesterol, BP and
glycosylated hemoglobin control. Therefore, the pharmacist ex-
plains the Dietary Approaches to Stop Hypertension (DASH) diet,
which has been demonstrated to lower BP.26 In addition to the
phone-based counseling, participants are given printed materials
that include both textual and pictorial information to reinforce what
was discussed.
EXERCISE
Considering participants’ current health characteristics and stage
of change, the pharmacist provides guidance on the benefits of
Table 1. Study Timeline
YEAR 1 YEAR 2 YEAR 3 YEAR 4
Pilot work X
Hire and train staff X X
Conduct enrollment X X X
Intervention follow-up X X X
Conducting analyses X X
Preparing reports and manuscripts X X
Each block with an X represents a 6-month time interval. For example, 6 months of pilot work is anticipated, 18
months to conduct enrollment (an average of 6 patients per week), and 18 months of intervention follow-up (12
months per patient).
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Table 2. Intervention Module and Associated Theoretical Constructs
MODULE CONTENT
THEORETICAL
CONSTRUCTS EXAMPLE QUESTIONS
DATA
SOURCE
1. Medication reconciliation
 Medication indication(s)
 Medication(s) safety for improved tolerance
 Proper drug administration
 Barriers to adherence
 Strategies to increase adherence
 Medication side effects
Perceived barriers,
susceptibility, and
benefits (HBM)
‘‘What is the main reason you changed/stopped taking this
medication(s) for your high blood pressure?’’
Responses include:
 Because of side effects
 My medication schedule is too complicated
 Cannot remember to take it
 Pill(s) too hard to swallow
 Afraid to take medications due to side effects
 Did not think it was working
 Do not think I need it
Pharmacist
intervention
2. Knowledge/risk perception of cardiovascular disease
 Patient-perceived risk of heart attack and stroke
 Education of modifiable and nonmodifiable risk factors
for CVD
 Risks of uncontrolled hypertension, cholesterol
 Benefits of therapy
 Appropriate goal setting to reduce CVD risk factors
Perceived severity
and threat (HBM)
‘‘How serious do you think it is to have high blood pressure?’’
Responses include:
 Very serious
 Serious
 A little serious
 Not at all serious
 Do not know
‘‘If over the next 6 months, you don’t change any of your
health behaviors related to CVD, what do you think is your
chance of having a stroke in the next year?’’ Responses
include:
 Very likely
 Likely
 Not likely
 Do not know
Patient interview
3. Health behaviors
 Education about weight management, diet, exercise,
smoking habits, and stress reduction as appropriate
given patients’ characteristics
 Importance of incorporating these as a lifestyle change
Self-efficacy (HBM) ‘‘On a scale of 1 to 10, with 1 being not at all hard and 10
being extremely hard, please rate how hard it is for you to
follow recommendations to improve your cardiovascular
health regarding diet?’’
‘‘On a scale of 1 to 10, with 1 being not at all hard and 10
being extremely hard, please rate how hard it is for you to
follow recommendations to improve your cardiovascular
health regarding exercise?’’
Patient interview
a. Weight management
 Importance of maintaining a healthy weight
 Setting reasonable weight management goals
Readiness to
change (TTM)
‘‘Based on your most recent weight at your doctor’s office,
you are above what guidelines say is ideal. Lowering your
weight can help control your heart risk factors. At this time
how ready are you to lose weight?’’ Responses include:
 Not ready to do anything at present
 Thinking about losing weight
 Preparing to lose weight
 Taking action to lose weight
Pharmacist
intervention
b. Diet
 Assessment of dietary habits (i.e., fruit and vegetable
consumption)
 Explanation of the DASH diet
 Sodium reduction; increase fiber and protein
consumption
 Understanding nutrition labels and portion control
 Opportunity to talk about portion control, healthy
carbohydrates, and heart-healthy diet in subsequent
encounters
Goal setting (HDM) ‘‘Now that we have talked about the benefits of weight loss, is
there a weight loss goal you could set for yourself to achieve
in 6 months?’’ Responses include:
 Open ended
Pharmacist
intervention
continued/
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increased physical activity, reinforces positive exercise behaviors,
and helps participants problem-solve regarding any functional im-
pairments or other barriers that limit physical activity. The phar-
macist uses motivational interviewing principles to help participants
set realistic exercise goals.
SMOKING
For participants who smoke at the time of contact, the pharmacist
employs motivational interviewing techniques and tailored inter-
vention materials geared toward smoking cessation. Barriers to ini-
tiating and maintaining smoking cessation, benefits of quitting, and
strategies to quit are discussed. Participants are also referred to local
resources including smoking cessation clinics and nicotine replace-
ment therapy. The delivery of nicotine replacement therapy is de-
termined by the number of cigarettes smoked per day.27 The
pharmacist prescribes nicotine replacement therapy based on these
principles.
MENTAL HEALTH, SLEEP, AND STRESS REDUCTION
Individuals reporting sleep problems are educated about the re-
lationship between elevated levels of stress and CVD symptoms. The
intervention materials address stress coping mechanisms, including
relaxation, meditation, referral to a sleep apnea clinic for a mask
adjustment (when appropriate), and the benefits of quality sleep.
PATIENT-ACTIVATED ENCOUNTER
Intervention participants are also able to initiate conversations
with the study pharmacist. Any emergent health issues that arise are
Table 2. Intervention Module and Associated Theoretical Constructs continued
MODULE CONTENT
THEORETICAL
CONSTRUCTS EXAMPLE QUESTIONS
DATA
SOURCE
c. Exercise
 Benefits of increased physical activity and positive
exercise behaviors
 Problem-solving regarding functional impairments and
other physical activity-limiting barriers
 Using motivational interviewing techniques goal setting
for exercising goals
Readiness to
change (TTM)
‘‘Physical activity lowers your cardiac risk factors, relieves
stress, and strengthens your heart, muscles, and bones. If you
are trying to lose weight, a combination of physical activity
and careful food choices can help you reach your target
weight and maintain it. You can start getting these benefits
even if you haven’t been very active in the past. At this time
how interested are you in changing your level of physical
activity?’’ Responses include:
 Not ready to do anything at present
 Taking action to lose weight
 Not ready to change at present
 Thinking about changing my activity level
 Preparing for changed activity level
 Already physically active
Pharmacist
intervention
d. Smoking
 Benefits of smoking cessation and risks of continued
smoking tailored to patient’s healthcare status and
concerns
 Initiating and maintaining smoking cessation goals
 Strategies to quit (i.e., local resources smoking cessation
clinics)
 Prescription for nicotine replacement therapy when
clinically indicated
Readiness to
change (TTM)
Goal setting (HDM)
‘‘How interested are you in quitting smoking or using tobacco
products?’’ Responses include:
 Not ready to quit yet
 Thinking about quitting
 Planning to quit soon
 In process of quitting
‘‘Now that we have talked about the benefits in stopping
smoking or using tobacco products, what goal, would you like
to set for yourself to achieve in 6 months?’’ Responses
include:
 Open ended
Pharmacist
intervention
e. Mental health, sleep, and stress reduction
 Screening for depression and posttraumatic stress
disorder
 Educating about the relationship between elevated
levels of stress and CVD symptoms
 Stress coping mechanisms (i.e., relaxation, meditation)
 Benefits of quality sleep
 When clinically indicated referral to appropriate
resources
Perceived severity
(HBM)
‘‘To what extent do you consider your sleep problem to
interfere with your daily functioning (e.g., daytime func-
tioning, ability to function at work/daily chores, concentra-
tion, memory, mood, etc.)?’’ Responses include:
 Not at all
 A little
 Somewhat
 Much
 Very much
 Do not know
Patient interview
The items listed are not exhaustive, but are intended to provide examples of questions that are used to tailor intervention content.
CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; HBM, health belief model; HDM, health decision model; TTM, transtheoretical model.
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immediately directed to participants’ primary care provider or other
provider as appropriate.
INTERVENTION TECHNIQUES
CITIES utilizes two intervention techniques—motivational inter-
views and home monitoring—to help patients progress through stages
of change. Motivational interviewing is a patient-centered commu-
nication method designed to explore and resolve ambivalence to
health behavior change.28,29 This technique has been demonstrated
effective in promoting healthy behaviors related to a myriad of CVD
risk factors. including diabetes,30–32 and is a patient-driven, com-
prehensive approach that can address behavioral, medical, and
psychosocial issues. Pharmacists are knowledgeable about appro-
priate health behaviors and typical barriers to adherence. Ad-
ditionally, contact with the study pharmacist may improve
continuity of care and facilitates communication about behavior
change between patients and an interdisciplinary care team.
The use of home monitoring of BP and blood glucose is an in-
creasingly common element of primary care. Home monitoring re-
quires minimal participant burden, yet equips participants with the
skills and information needed for engagement in their disease
management. Home monitoring also provides more frequent mea-
surement readings than collected in a clinic setting, where appoint-
ments are often months apart.33 During monthly phone calls, patients
report a continuous stream of readings enabling the pharmacist to
respond to participants’ home-monitored values in between clinic
visits, thus filling an important gap in patient-centered care. In order
to inform medication adjustment the pharmacist requires, on aver-
age, at least three BP readings weekly. Similarly, patients with dia-
betes provide blood glucose readings at least once weekly. Patients
may report more frequent readings if prescribed multiple daily in-
sulin injections for management of their diabetes.
CONTROL GROUP
Participants randomized to the control group continue to be
managed by their primary care provider and usual healthcare team.
The control group has no contact with the study pharmacist and is not
instructed to monitor BP and/or blood glucose levels at home.
Results
Patient enrollment began on November 1, 2011 and is ongoing. As
of April 2013, CITIES had reviewed records and/or contacted 2,906
unique patients associated with the Durham VAMC. Of those patients,
969 (24%) were either ineligible or refused, 356 (12%) have been
enrolled, and 1,581 (54%) remain in the enrollment queue. This
equates with an enrollment rate of between 30% and 45%.
Discussion
The CITIES intervention is a theory-driven, pharmacist-admin-
istered, telephone intervention. The theoretical models supporting
the intervention inform both the structure and flow of the modules.
Home-based monitoring and telephone-based care can alleviate
strain on both patients and the healthcare system by increasing
efficiency and communication between patient and provider.
Home-based care encourages patients to become more actively
engaged in managing their health. This is critical because over half
of patients cease taking their antihypertensive and other CVD-
related drugs within their first year of treatment.34–36 Adherent
patients have better health outcomes than nonadherent patients,
even when taking a placebo.37 By equipping patients with educa-
tional and behavioral tools at home, we may help them reduce their
CVD risk.
We use a pharmacist interventionist. Pharmacists are skilled in
counseling patients about health benefits of making lifestyle chan-
ges, motivating patients through stages of change and proper med-
ication administration, and in providing strategies to increase
medication adherence. Pharmacists also facilitate quality commu-
nication between patient and primary care provider by helping pa-
tients understand how they can engage in self-management and
when physician involvement is needed. Providing care over the
telephone reduces cost both to the patient in terms of travel and time
burden and to the healthcare system in terms of opening clinic ap-
pointments for patients with complex or acute health needs.
Despite these advantages, limitations must be addressed. With
increasing technology, there are a myriad of mechanisms for inter-
vention administration. Some of these include remotely monitoring
pillbox openings, transferring self-monitored data remotely, and
text-messaging patients with medication changes. The effectiveness
of these high-resource technologies has, in most cases, not neces-
sarily been tested. The relatively low-technology design of CITIES
was carefully chosen because of the potential for broad dissemination
without a substantial increase in required resources. Participants in
the intervention group are provided with home monitoring equip-
ment and are trained in its proper utilization. However, it is possible
that participants may either incorrectly measure their BP or inac-
curately report it. Moreover, to assess adherence we used a valid,
reliable measure,38 but there are potential issues with participants
underreporting their nonadherence. We chose to rely on self-reported
data because, given the VA’s emphasis on patient-centered care, a
focus on self-reported measures was appropriate.
The CITIES intervention is designed to increase adherence and
build participant engagement in self-monitoring and management of
hypertension and other CVD risk factors. By working on multiple risk
factors in unison, we anticipate progression through stages of
changed resulting in improvements in self-reported medication ad-
herence and clinical values. The study includes common educational
models, as well as tailored participant-specific information based on
the baseline interview assessment. This results in variable time re-
quired for the monthly intervention telephone calls. Given the in-
creasing population of older adults, complexity of managing patients
with multiple chronic conditions, and resulting increasing burden on
primary care teams, interventions demonstrating improvements
across multiple behaviors while training patients to manage their
own health are an efficient, effective method for both healthcare cost
reduction and improved care quality.
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Many adults with multiple CVD risk factors continue to be non-
adherent with their medication and health behaviors, despite clini-
cians’ guidance. The goal of the CITIES intervention is to maintain
disease control, increase medication adherence, and improve health
behaviors for CVD risk reduction. Translation of these findings into
clinical practice will be enhanced by the practical design and re-
producibility of the intervention.
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